CoronaryAtlas logo
CoronaryAtlas
CK-MB
Pathway / Myocardial injury (shared endpoint)

CK-MB

CKMprotein

CK-MB is a cardiac enzyme released following myocardial necrosis and serves as a diagnostic and prognostic biomarker of infarct size and adverse outcomes in acute MI.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleCardiac-specific isoform of creatine kinase released upon cardiomyocyte necrosis; AMI diagnostic and prognostic marker.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000104879

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
50
A — assay feasibility
96
E — evidence strength
100
T1DI (composite)
68
Specificity differential (R−C)+40.7
Direct evidence: higher in Type I (D=+2)
CK-MB levels/rises were higher in Type-1 MI compared to Type-2 MI patients in studies directly comparing the two groups.
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 0
3hypovolemia / dehydrationmag 2
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuremag 2
6hypertensive emergencymag 1
7high-demand / peri-operative stressmag 2
Coverage: 6/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 17 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top)
Method / principle
Chemiluminescent sandwich immunoassay (mass); or enzymatic activity
Reagent / substrate
Anti-CK-MB antibody pair (mass); or CK-MB immunoinhibition + coupled hexokinase/G6PD (activity)
Platform
Automated core-lab analyzer
Turnaround · availability
STAT–routine · FDA-cleared

Literature evidence(51)

Showing 40 of 51 linked references.

Clinical trials(1)